130 related articles for article (PubMed ID: 30912678)
1. Preparation, characterization and
Amer AM; Allam AN; Abdallah OY
Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678
[TBL] [Abstract][Full Text] [Related]
2. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
3. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies.
Amer AM; Allam AN; Abdallah OY
AAPS PharmSciTech; 2018 Feb; 19(2):661-667. PubMed ID: 28948575
[TBL] [Abstract][Full Text] [Related]
4. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
5. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
6. A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
J Pharm Sci; 2019 Nov; 108(11):3599-3608. PubMed ID: 31348934
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
Shaikh SM; Avachat AM
Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic and Quantum Chemistry Characterization of Candesartan Cilexetil: Importance for the Correct Drug Classification According to Biopharmaceutics Classification System.
de Campos DP; Silva-Barcellos NM; Lima RR; Savedra RML; Siqueira MF; Yoshida MI; da Nova Mussel W; de Souza J
AAPS PharmSciTech; 2018 Oct; 19(7):3019-3028. PubMed ID: 30062540
[TBL] [Abstract][Full Text] [Related]
9. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug.
Aly UF; Sarhan HA; Ali TFS; Sharkawy HAE
Drug Des Devel Ther; 2020; 14():1851-1865. PubMed ID: 32523332
[TBL] [Abstract][Full Text] [Related]
10. Solid dispersion systems for enhanced dissolution of poorly water-soluble candesartan cilexetil: In vitro evaluation and simulated pharmacokinetics studies.
Ali ISM; Sajad UA; Abdul Rasool BK
PLoS One; 2024; 19(6):e0303900. PubMed ID: 38843120
[TBL] [Abstract][Full Text] [Related]
11. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
[TBL] [Abstract][Full Text] [Related]
12. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
13. Mixed Pluronic/lecithin micelles formulation for oral bioavailability of candesartan cilexetil drug:
Mahajan H; Patel HS; Ray D; Aswal VK; Sharma RK; Tandel H
Drug Dev Ind Pharm; 2024 Jan; 50(1):23-35. PubMed ID: 38079333
[TBL] [Abstract][Full Text] [Related]
14. The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil.
Ertürk AS; Gürbüz MU; Tülü M
Pharm Dev Technol; 2017 Feb; 22(1):111-121. PubMed ID: 27484586
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
[TBL] [Abstract][Full Text] [Related]
16. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
Ntountaniotis D; Andreadelis I; Kellici TF; Karageorgos V; Leonis G; Christodoulou E; Kiriakidi S; Becker-Baldus J; Stylos EK; Chatziathanasiadou MV; Chatzigiannis CM; Damalas DE; Aksoydan B; Javornik U; Valsami G; Glaubitz C; Durdagi S; Thomaidis NS; Kolocouris A; Plavec J; Tzakos AG; Liapakis G; Mavromoustakos T
Mol Pharm; 2019 Mar; 16(3):1255-1271. PubMed ID: 30681344
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
[TBL] [Abstract][Full Text] [Related]
18. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
Surampalli G; Nanjwade BK; Patil PA; Chilla R
Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
[TBL] [Abstract][Full Text] [Related]
19. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
Eur J Pharm Sci; 2017 Nov; 109():503-513. PubMed ID: 28889028
[TBL] [Abstract][Full Text] [Related]
20. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
Zhang Z; Gao F; Bu H; Xiao J; Li Y
Nanomedicine; 2012 Jul; 8(5):740-7. PubMed ID: 21930110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
